Why the study?
Do T-type (mibefradil) and L-type (amlodipine) calcium antagonists improve systemic, renal, and glomerular hemodynamics in spontaneously hypertensive rats with L-NAME-exacerbated nephrosclerosis?
Population
17-week-old male spontaneously hypertensive rats (SHR)
Comparison
Mibefradil or amlodipine administered… vs Control group (no treatment) or L-NAME alone
Design
Preclinical
Follow-up
Up to 6 weeks
Authors
Loading...
Hypothesis-generating for T-type calcium blockade in hypertensive nephrosclerosis models; human trials required before any clinical consideration.
Do T-type (mibefradil) and L-type (amlodipine) calcium antagonists improve systemic, renal, and glomerular hemodynamics in spontaneously hypertensive rats with L-NAME-exacerbated nephrosclerosis?
In a rat model of hypertensive nephrosclerosis, both T-type and L-type calcium antagonists improved hemodynamics and reversed pathological alterations, with the T-type antagonist mibefradil showing greater efficacy in reducing afferent arteriolar resistance.
Nakamura et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: